Agenus (NASDAQ:AGEN) Receives New Coverage from Analysts at B. Riley

B. Riley started coverage on shares of Agenus (NASDAQ:AGEN) in a research report sent to investors on Tuesday, The Fly reports. The firm issued a buy rating and a $6.00 price target on the biotechnology company’s stock.

Several other brokerages also recently weighed in on AGEN. ValuEngine raised Agenus from a sell rating to a hold rating in a report on Tuesday, November 12th. BidaskClub upgraded Agenus from a sell rating to a hold rating in a research note on Monday, November 11th.

Shares of AGEN stock traded up $0.01 during trading hours on Tuesday, reaching $4.36. 2,678,993 shares of the company’s stock were exchanged, compared to its average volume of 1,209,492. Agenus has a fifty-two week low of $1.95 and a fifty-two week high of $4.57. The stock’s 50 day moving average is $2.92 and its 200-day moving average is $2.80. The company has a market cap of $510.98 million, a price-to-earnings ratio of -3.03 and a beta of 1.84.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.05. The business had revenue of $19.94 million during the quarter, compared to analyst estimates of $15.60 million. On average, equities research analysts forecast that Agenus will post -0.96 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its holdings in shares of Agenus by 28.3% during the second quarter. JPMorgan Chase & Co. now owns 28,741 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 6,332 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in Agenus in the second quarter valued at approximately $40,000. Acadian Asset Management LLC increased its holdings in Agenus by 227.7% in the 2nd quarter. Acadian Asset Management LLC now owns 195,172 shares of the biotechnology company’s stock worth $586,000 after buying an additional 135,617 shares during the period. Alps Advisors Inc. acquired a new position in Agenus in the 2nd quarter worth approximately $843,000. Finally, Vanguard Group Inc. increased its holdings in Agenus by 16.7% in the 2nd quarter. Vanguard Group Inc. now owns 5,540,211 shares of the biotechnology company’s stock worth $16,620,000 after buying an additional 793,180 shares during the period. 36.69% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Read More: Inverted Yield Curve

The Fly

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with's FREE daily email newsletter.